Mark S. Sapienza, MD

I see patients at the following locations:

Education

Bachelor’s Degree – Franklin & Marshall College

Medical Degree – Loyola University – Stritch School of Medicine

Internship – Thomas Jefferson University Hospital

Residency – Thomas Jefferson University Hospital

Fellowship – Thomas Jefferson University Hospital

Board Certifications – Internal Medicine, Gastroenterology

Honors & Awards

  • Top Doctors 2024, Bergen Magazine
  • Clinical Teaching Award 2003, Englewood Hospital
  • Top Doctors 2008, 2013, 2016-2020 NJ Magazine
  • Top Doctors 2012-2016, 201 Magazine
  • Doctor of the Year 2015, Englewood Hospital
  • New York Magazine: Top Doctors: 2016, 2018, 2020
  • Castle Connolly Regional Top Doctors: 1st Edition
  • Jersey’s Best Magazine Top Doctors: 2016, 2017, 2018, 2019
  • Top Doctors New York Metro Area (digital guide): 2016, 2017, 2018, 2019, 2020, 2021

Specialties & Main Areas of Interest

  • Liver Disease
  • Inflammatory Bowel Disease

Hospital Affiliations

  • Englewood Hospital
  • Holy Name Hospital
  • Hackensack Meridian School of Medicine – Assistant Professor in the Department of Medicine (non-clinical affiliation)

Other Appointments

  • Chief, Section of Gastroenterology, 2016-current
  • Associate Chief, Section of Gastroenterology, 2010-2016
  • Chair, EHMC Credentials Committee, 2013
  • P&T Committee at Englewood Hospital P&T Committee, 2003-current
  • President of NJ Gastroenterology & Endoscopy Society (NJGES), 2006-2007
  • President of NJ Gastrointestinal PAC (GIPAC), 2007-2014
  • Secretary/Treasurer, EHMC Medical Staff, 2014-2016
  • Vice President, EHMC Medical Staff, 2016-2018
  • President, EHMC Medical Staff, 2018-2020
  • EHMC Hospital Board Member (ex officio), 2016-current

Research

  • Yellowstone Study – Principal Investigator. Multi center clinical research trial to determine if the investigational medication ozanimod is safe and effective for the treatment of moderately to severe active Crohn’s disease
  • PN 943-03 Study – Principal Investigator. A phase II randomized double blind placebo-controlled multi-center study to evaluate the safety and efficacy of oral PN-943 in subjects with moderate to severe active ulcerative coliti

Schedule Your Colonoscopy

Choose a Location